Fox 2005

Methods	RCT Length of follow‐up: 6 months
Participants	All children living in endemic area Number analysed for primary outcome: 626 Age range: 5 to 11 years Inclusion criteria: children aged 5 to 11 years attending any of 12 primary schools in Haiti where no other deworming activity was taking place Exclusion criteria: none stated
Interventions	Single dose vs placebo Albendazole 400 mg plus placebo (250 mg vitamin C tablet); 6 mg/kg diethylcarbamazine (DEC) plus placebo (250 mg vitamin C tablet); Albendazole 400 mg plus single dose of 6 mg/kg diethylcarbamazine (DEC); Placebo plus placebo (2 x 250 mg vitamin C tablets).
Outcomes	Weight: final and change in weight; Height: final and change in height; Adverse effects. Not included in review: worm intensity and prevalence; microfilarial density.
Notes	Location: Haiti Community category: 2 Weight and height outcomes are only presented for a subgroup of children infected with Trichuris Source of funding: Emerging Infections Program of the Centers for Disease Control and Prevention (CDC) and an Institutional Strengthening Grant from the WHO to the Hopital Sainte Croix.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random‐number table.
Allocation concealment (selection bias)	Low risk	Centrally‐coded allocation system broken after baseline measures taken.
Blinding (performance bias and detection bias) All outcomes	Low risk	"Double‐blind". Laboratory personnel, measurement teams and personnel evaluating students for adverse reactions were all blinded.
Incomplete outcome data (attrition bias) All outcomes	Low risk	626/646 participants analysed for the primary outcome. Reasons for loss to follow‐up unclear. Inclusion of all randomized participants (number evaluable/number randomized): 97% (626/646).
Selective reporting (reporting bias)	Low risk	All stated outcomes reported.
Other bias	Low risk	No obvious other source of bias.